Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Pimobendan and its effects on life quality
Pimobendan is a very popular drug in dogs. In this brandnew summary its effects on the life quality and survival time in diseases like dilated cardiomyopathy and chronic degenerative valvular disease are studied. Very interesting!

Pimobendan is a novel agent with properties that are highly desirable in the clinical management of congestive heart failure (CHF) secondary to both dilated cardiomyopathy (DCM) and chronic degenerative valvular disease in dogs.

Review of available data suggests that pimobendan is safe, well tolerated, and leads to enhanced quality of life in dogs with CHF secondary to DCM or chronic valvular disease when used in combination with furosemide or other conventional therapies (e.g., angiotensin-converting enzyme inhibitors, digoxin).

Pimobendan leads to a reduction in mortality from CHF associated with DCM, and ongoing studies are evaluating its effects on mortality associated with chronic valvular disease.



Source:
Sonya G. Gordon, Matthew W. Miller, Ashley B. Saunders (2006): Pimobendan in Heart Failure Therapy – A Silver Bullet? In: Journal of the American Animal Hospital Association 42:90-93 (2006)



Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

RET-He to diagnose iron-deficient erythropoiesis in dogsmembers
Reticulocyte hemoglobin content provided by the Siemens ADVIA (CHr) is an established marker of iron deficiency. The IDEXX ProCyte Dx hematology analyzer now provides a similar variable, reticulocyte hemoglobin equivalent (RET-He).
The objectives of this study were to evaluate RET-He and its diagnostic utility in dogs, and to calculate a cutoff value for diagnosing iron-deficient erythropoiesis (IDE).

  • Platelet indices in dogs with septic peritonitis
  • Hypertriglyceridemia-Associated Proteinuria in Miniature Schnauzersmembers
  • Gastrointestinal dysmotility disorders in critically ill animalsmembers
  • Disorder of sex development in a cat with chromosome mosaicism members
  • Generalized discoid lupus erythematosus in dogs members
  • Epidermolysis bullosa acquisita in dogsmembers
  • Chiari-Like Malformation and Syringomyelia in American Brussels Griffon Dogsmembers
  • Efficacy and Potential Complications of Transjugular Liver Biopsymembers
  • Hypomagnesemia in Brachycephalic Dogsmembers
  • Comparison of two minimally invasive techniques for liver biopsy members
  • Topical aqueous sirolimus and the tear production members
  • JAK 1/2 inhibitor in the treatment of canine B-cell lymphomamembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved